2025年07月, 北海道大学医学部放射線治療学教室同門会, 若手奨励賞　　　　　　　　　　　　　　　
小泉富基

2024年06月, 第150回日本医学放射線学会北日本地方会・第95回日本核医学会北日本地方会, 優秀演題賞　　　　　　　　　　　　　　　
小泉富基

2022年03月, 臨床放射線, 臨放症例賞　　　　　　　　　　　　　　　
小泉富基

Prospective Registry and Meta-Analysis of Particle Therapy for Hepatocellular Carcinoma: Clinical Outcomes and Real-World Impact　　　　　　　　　　　　　　　
Masashi Mizumoto, Kei Shibuya, Kazuki Terashima, Hiromitsu Iwata, Takashi Saito, Shingo Toyama, Takashi Ogino, Masao Murakami, Tatsuya Ohno, Yoshitaka Sato, Tetsuo Akimoto, Hiroyuki Katoh, Masaru Wakatsuki, Takahiro Waki, Norio Katoh, Fuki Koizumi, Masayuki Araya, Tsuyoshi Onoe, Masaru Takagi, Tomoaki Okimoto, Hiroyuki Ogino, Haruko Numajiri, Yoshiyuki Shioyama, Takayuki Hashimoto, Hisateru Ohba, Shoji Kubo, Kiyoshi Hasegawa, Kazushi Maruo, Hidefumi Aoyama, Hideyuki Sakurai
Cancer Medicine.15(3): e71639, 2026年02月, ［査読有り］

Evaluation of intra-fractional target displacement by patient motion during a single-isocenter multi-target stereotactic radiation therapy for brain metastases.
Ryota Yamada, Takaaki Yoshimura, Ryo Murata, Kentaro Nishioka, Takashi Mori, Fuki Koizumi, Yoshihiro Fujita, Shuhei Takahashi, Takahiro Hattori, Takahiro Kanehira, Kohei Yokokawa, Rie Yamazaki, Kenji Horita, Hiroshi Tamura, Yamato Wakabayashi, Yuta Ichiu, Takayuki Hashimoto, Hidefumi Aoyama
Journal of applied clinical medical physics, 26, 9, e70219, 2025年09月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: Single-isocenter multi-target volumetric modulated arc therapy (SIMT-VMAT) has been implemented widely in fractionated stereotactic radiosurgery (fSRS) to treat brain metastases. The impact of rotational intra-fractional patient motion (IFPM) is influenced by the distance between the geometric target's center and the isocenter (DTI). PURPOSE: We hypothesized that IFPM's impact on each target would increase with greater DTI during fSRS. Therefore, we aimed to estimate the intra-fractional target displacement (IFTD), which represents each target's displacement caused by translational and rotational components of IFPM. METHODS: In this study, we involved 35 patients with 2-13 brain metastases, all of whom had previously undergone SIMT-VMAT fSRS. All patients were immobilized using a clamshell-style device, with 28 using a biteplate. Cone beam computed tomography (CBCT) images were obtained at the same imaging center before and after treatment. The IFPM was calculated using both CBCT datasets. The IFTD was determined by comparing the planned target coordinates with the actual coordinates while factoring in IFPM. RESULTS: We evaluated 136 targets. The mean IFTD was 0.38 mm (95% confidence interval [CI]: 0.37-0.40 mm) with the biteplate and 0.65 mm (95% CI: 0.59-0.71 mm) without it. A very weak positive correlation was observed between DTI and IFTD despite the immobilization method. This correlation indicates that the distance dependence of IFTD is nearly negligible. CONCLUSION: The findings showed that the impact of IFPM on each target demonstrated minimal dependence on the DTI. Displacement was relatively consistent regardless of the target location. In addition, the use of a biteplate was suggested to potentially reduce these effects.

Normal tissue complication probability model for severe radiation-induced lymphopenia in patients with pancreatic cancer treated with concurrent chemoradiotherapy.
Fuki Koizumi, Norio Katoh, Takahiro Kanehira, Yasuyuki Kawamoto, Toru Nakamura, Tatsuhiko Kakisaka, Miyako Myojin, Noriaki Nishiyama, Akio Yonesaka, Manami Otsuka, Rikiya Takashina, Hideki Minatogawa, Hajime Higaki, Yusuke Uchinami, Hiroshi Taguchi, Kentaro Nishioka, Koichi Yasuda, Naoki Miyamoto, Isao Yokota, Keiji Kobashi, Hidefumi Aoyama
Physics and imaging in radiation oncology, 33, 100690, 100690, 2025年01月, ［査読有り］, ［筆頭著者］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND AND PURPOSE: Radiation-induced lymphopenia (RIL) may be associated with a worse prognosis in pancreatic cancer. This study aimed to develop a normal tissue complication probability (NTCP) model to predict severe RIL in patients with pancreatic cancer undergoing concurrent chemoradiotherapy (CCRT). MATERIALS AND METHODS: We reviewed pancreatic cancer patients treated at our facility for model training and internal validation. Subsequently, we reviewed data from three other facilities to validate model fit externally. An absolute lymphocyte count (ALC) of ＜0.5 × 103/μL during CCRT was defined as severe RIL. An NTCP model was trained using a least absolute shrinkage and selection operator (LASSO)-based logistic model. The model's predictive performance was evaluated using the receiver operating characteristic area under the curve (AUC), scaled Brier score, and calibration plots. RESULTS: Among the 114 patients in the training set, 78 had severe RIL. LASSO showed that low baseline ALC, large planning target volume, and high percentage of bilateral kidneys receiving ≥ 5Gy were selected as parameters of the NTCP model for severe RIL. The AUC and scaled Brier score were 0.91 and 0.49, respectively. Internal validation yielded an average AUC of 0.92. In the external validation with 68 patients, the AUC and scaled Brier score was 0.83 and 0.30, respectively. Calibration plots showed good conformity. CONCLUSIONS: The NTCP model for severe RIL during CCRT for pancreatic cancer, developed and validated in this study, demonstrated good predictive performance. This model can be used to evaluate and compare the risk of RIL.

Radiotherapy with or without chemotherapy for locally advanced head and neck cancer in elderly patients: analysis of the Head and Neck Cancer Registry of Japan.
Koichi Yasuda, Yusuke Uchinami, Satoshi Kano, Jun Taguchi, Daisuke Kawakita, Megumi Kitayama, Kentaro Nishioka, Takashi Mori, Fuki Koizumi, Yuri Fujii, Yasushi Shimizu, Keiji Kobashi, Seiichi Yoshimoto, Ken-Ichi Nibu, Akihiro Homma, Hidefumi Aoyama
International journal of clinical oncology, 29, 3, 241, 247, 2024年03月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: Whether concurrent chemotherapy with radiotherapy (CRT) is effective for elderly patients with head and neck cancer is a controversial topic. This study aimed to analyze the effectiveness of CRT vs. radiation therapy (RT) among elderly patients in Japan. METHODS: Data from the Head and Neck Cancer Registry of Japan were extracted and analyzed. Patients with locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, or larynx who received definitive CRT or RT between 2011 and 2014 were included. RESULTS: CRT was administered to 78% of the 1057 patients aged ≥ 70 years and 67% of the 555 patients aged ≥ 75 years. For the patients aged ≥ 75 years, the overall survival (OS) rate was significantly better in the CRT group than in the RT group (P < 0.05), while the progression-free survival (PFS) rate was not significantly different (P > 0.05). The add-on effect of CRT was significantly poor in elderly patients (P < 0.05), and it was not a significant factor in the multivariate analysis for patients aged ≥ 75 years. After propensity score matching, there were no significant differences in the OS and PFS rates between the patients aged ≥ 70 years and those aged ≥ 75 years (all, P > 0.05). CONCLUSION: Although aggressive CRT is administered to elderly patients in Japan, its effectiveness is uncertain. Further prospective randomized trials are needed to verify whether CRT is superior to RT alone for elderly patients.

Distribution of human papilloma virus genotypes and treatment outcomes in definitive radiotherapy for cervical cancer.
Rumiko Kinoshita, Takashi Mitamura, Fumi Kato, Takahiro Hattori, Hajime Higaki, Shuhei Takahashi, Yoshihiro Fujita, Manami Otsuka, Fuki Koizumi, Yusuke Uchinami, Takashi Mori, Kentaro Nishioka, Takayuki Hashimoto, Yoichi M Ito, Hidemichi Watari, Hidefumi Aoyama
Journal of radiation research, 64, 2, 463, 470, 2023年03月23日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, Most oncogenic human papilloma virus (HPV) genotypes stratify into two species, α-7 HPV and α-9 HPV. There are several studies that evaluate the relationship between HPV species and treatment outcomes and reports that HPV species is prognostic. The HPV genotyping was conducted using biopsy specimens which had been stored in these studies. We conducted the study using the HPV test performed by cytology specimens which is less invasive and more useful in clinical settings. This study enrolled 46 patients who received HPV genotyping before the definitive radiotherapy. The results of the HPV genotyping were classified into HPVα-7, HPVα-9 and negatives. Of the 46 patients, 10 were positive for HPVα-7, 21 positive for HPVα-9 and 15 were negative. The median follow-up period was 38 months (range 4-142). The HPVα-7, HPVα-9 and negative groups showed the 3-year overall survival (OS; 59.3%, 80.4% and 72.2% [P = 0.25]); local control (LC; 67.5%, 81% and 80% [P = 0.78]); pelvic control (PC) (50%, 81% and 72.7% [P = 0.032]); pelvic lymph node (PLN) control (78.7%, 95% and 92.3% [P = 0.012]); distant metastasis free (DMF) survival (50%, 75.4% and 42.8% [P = 0.098]); and progression free survival (PFS) rate of patients (30%, 66.7% and 38.9% [P = 0.085]), respectively. Patients with HPVα-7 showed statistically significant poorer PC than the HPVα-9 group, in multivariate analysis. This result is consistent with previous studies for HPV positive patients. The HPV negativity rate was higher in this study than in other studies and further work on this may be needed for clinical use.

Evaluation of short-term gastrointestinal motion and its impact on dosimetric parameters in stereotactic body radiation therapy for pancreatic cancer.
Yusuke Uchinami, Takahiro Kanehira, Yoshihiro Fujita, Naoki Miyamoto, Kohei Yokokawa, Fuki Koizumi, Motoyasu Shido, Shuhei Takahashi, Manami Otsuka, Koichi Yasuda, Hiroshi Taguchi, Keiji Nakazato, Keiji Kobashi, Norio Katoh, Hidefumi Aoyama
Clinical and translational radiation oncology, 39, 100576, 100576, 2023年03月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: The aim of this study is to quantify the short-term motion of the gastrointestinal tract (GI-tract) and its impact on dosimetric parameters in stereotactic body radiation therapy (SBRT) for pancreatic cancer. METHODS: The analyzed patients were eleven pancreatic cancer patients treated with SBRT or proton beam therapy. To ensure a fair analysis, the simulation SBRT plan was generated on the planning CT in all patients with the dose prescription of 40 Gy in 5 fractions. The GI-tract motion (stomach, duodenum, small and large intestine) was evaluated using three CT images scanned at spontaneous expiration. After fiducial-based rigid image registration, the contours in each CT image were generated and transferred to the planning CT, then the organ motion was evaluated. Planning at risk volumes (PRV) of each GI-tract were generated by adding 5 mm margins, and the volume receiving at least 33 Gy (V33) < 0.5 cm3 was evaluated as the dose constraint. RESULTS: The median interval between the first and last CT scans was 736 s (interquartile range, IQR:624-986). To compensate for the GI-tract motion based on the planning CT, the necessary median margin was 8.0 mm (IQR: 8.0-10.0) for the duodenum and 14.0 mm (12.0-16.0) for the small intestine. Compared to the planned V33 with the worst case, the median V33 in the PRV of the duodenum significantly increased from 0.20 cm3 (IQR: 0.02-0.26) to 0.33 cm3 (0.10-0.59) at Wilcoxon signed-rank test (p = 0.031). CONCLUSION: The short-term motions of the GI-tract lead to high dose differences.

Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study.
Hajime Higaki, Kentaro Nishioka, Manami Otsuka, Noboru Nishikawa, Motoyasu Shido, Hideki Minatogawa, Yukiko Nishikawa, Rikiya Takashina, Takayuki Hashimoto, Norio Katoh, Hiroshi Taguchi, Rumiko Kinoshita, Koichi Yasuda, Takashi Mori, Yusuke Uchinami, Fuki Koizumi, Yoshihiro Fujita, Shuhei Takahashi, Takahiro Hattori, Noriaki Nishiyama, Hidefumi Aoyama
Radiation oncology (London, England), 18, 1, 25, 25, 2023年02月07日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: The Graded Prognostic Assessment for lung cancer using molecular markers (Lung-molGPA) has not been validated for use with Japanese non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) and the factors impacting survival need to be assessed. METHODS: We retrospectively analyzed 294 NSCLC patients who were newly diagnosed with BM between 2013 and 2020 and had received radiotherapy for BM initially at the Hokkaido Cancer Center. We evaluated the effect on the prognosis of Lung-molGPA items, the expression of PD-L1 (classified as high, low, and no expression), and the treatment history. The main outcome was the survival measured from the day of the diagnosis of BM, and log-rank tests were performed to evaluate the results. RESULTS: The median overall survival (OS) times for adenocarcinoma by groups of GPA scores (0‒1.0, 1.5‒2.0, 2.5‒3.0, and 3.5‒4.0) were 5.5, 14.8, 28.3, and 39.0 months (p < 0.0001), respectively. The median survival times for non-adenocarcinoma by groups of GPA scores (0‒1.0, 1.5‒2.0, and 2.5‒3.0) were 3.2, 11.0, and 16.0 months (p = 0.0011), respectively. In adenocarcinoma patients with gene mutations, osimertinib significantly improved the outcome (median OS: 34.2 and 17.6 months with and without osimertinib, respectively (p = 0.0164)). There was no significant difference in the OS between patients who were initially treated with tyrosine-kinase inhibitor for BM and those who initially received radiotherapy (p = 0.5337). In patients tested for PD-L1 expression, the median survival times after the diagnosis of BM were 5.6, 22.5, and 9.3 months for the high-, low- and no-expression groups (p = 0.2198), respectively. Also, in patients with high PD-L1 expressions, those with ICI had survival (median OS, 8.6 months) than those without (median OS, 3.6 months). CONCLUSIONS: We confirmed that Lung-molGPA successfully classified Japanese NSCLC patients with BM by the prognosis. Osimertinib prolonged survival of EGFR-positive NSCLC patients with BM, and ICI was effective in patients with high PD-L1 expressions.

Predicting the daily gastrointestinal doses of stereotactic body radiation therapy for pancreatic cancer based on the shortest distance between the tumor and the gastrointestinal tract using daily computed tomography images.
Yusuke Uchinami, Takahiro Kanehira, Keiji Nakazato, Yoshihiro Fujita, Fuki Koizumi, Shuhei Takahashi, Manami Otsuka, Koichi Yasuda, Hiroshi Taguchi, Kentaro Nishioka, Naoki Miyamoto, Kohei Yokokawa, Ryusuke Suzuki, Keiji Kobashi, Keita Takahashi, Norio Katoh, Hidefumi Aoyama
BJR open, 5, 1, 20230043, 20230043, 2023年, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, OBJECTIVES: We aimed to investigate whether daily computed tomography (CT) images could predict the daily gastroduodenal, small intestine, and large intestine doses of stereotactic body radiation therapy (SBRT) for pancreatic cancer based on the shortest distance between the gross tumor volume (GTV) and gastrointestinal (GI) tract. METHODS: Twelve patients with pancreatic cancer received SBRT of 40 Gy in five fractions. We recalculated the reference clinical SBRT plan (PLANref) using daily CT images and calculated the shortest distance from the GTV to each GI tract. The maximum dose delivered to 0.5 cc (D0.5cc) was evaluated for each planning at-risk volume of the GI tract. Spearman's correlation test was used to determine the association between the daily change in the shortest distance (Δshortest distance) and the ratio of ΔD0.5cc dose to D0.5cc dose in PLANref (ΔD0.5cc/PLANref) for quantitative analysis. RESULTS: The median shortest distance in PLANref was 0 mm in the gastroduodenum (interquartile range, 0-2.7), 16.7 mm in the small intestine (10.0-23.7), and 16.7 mm in the large intestine (8.3-28.1 mm). The D0.5cc of PLANref in the gastroduodenum was >30 Gy in all patients, with 10 (83.3%) having the highest dose. A significant association was found between the Δshortest distance and ΔD0.5cc/ PLANref in the small or large intestine (p < 0.001) but not in the gastroduodenum (p = 0.404). CONCLUSIONS: The gastroduodenum had a higher D0.5cc and predicting the daily dose was difficult. Daily dose calculations of the GI tract are recommended for safe SBRT. ADVANCES IN KNOWLEDGE: This study aimed to predict the daily doses in SBRT for pancreatic cancer from the shortest distance between the GTV and the gastrointestinal tract.Daily changes in the shortest distance can predict the daily dose to the small or large intestines, but not to the gastroduodenum.

A study on predicting cases that would benefit from proton beam therapy in primary liver tumors of less than or equal to 5 cm based on the estimated incidence of hepatic toxicity.
Yusuke Uchinami, Norio Katoh, Ryusuke Suzuki, Takahiro Kanehira, Masaya Tamura, Seishin Takao, Taeko Matsuura, Naoki Miyamoto, Yoshihiro Fujita, Fuki Koizumi, Hiroshi Taguchi, Koichi Yasuda, Kentaro Nishioka, Isao Yokota, Keiji Kobashi, Hidefumi Aoyama
Clinical and translational radiation oncology, 35, 70, 75, 2022年07月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: For small primary liver tumors, favorable outcomes have been reported with both of proton beam therapy (PBT) and X-ray therapy (XRT). However, no clear criteria have been proposed in the cases for which and when of PBT or XRT has to be used. The aim of this study is to investigate cases that would benefit from PBT based on the predicted rate of hepatic toxicity. MATERIALS AND METHODS: Eligible patients were those who underwent PBT for primary liver tumors with a maximum diameter of ≤ 5 cm and Child-Pugh grade A (n = 40). To compare the PBT-plan, the treatment plan using volumetric modulated arc therapy was generated as the XRT-plan. The rate of predicted hepatic toxicity was estimated using five normal tissue complication probability (NTCP) models with three different endpoints. The differences in NTCP values (ΔNTCP) were calculated to determine the relative advantage of PBT. Factors predicting benefits of PBT were analyzed by logistic regression analysis. RESULTS: From the dose-volume histogram comparisons, an advantage of PBT was found in sparing of the normal liver receiving low doses. The factors predicting the benefit of PBT differed depending on the selected NTCP model. From the five models, the total tumor diameter (sum of the target tumors), location (hepatic hilum vs other), and number of tumors (1 vs 2) were significant factors. CONCLUSIONS: From the radiation-related hepatic toxicity, factors were identified to predict benefits of PBT in primary liver tumors with Child-Pugh grade A, with the maximum tumor diameter of ≤ 5 cm.

北海道大学病院放射線治療科関連施設における子宮頸癌に対する根治放射線治療に関するアンケート結果について—The survey of definitive radiotherapy for cervical cancer in affiliate facilities of department of radiation oncology Hokkaido University Hospital
木下 留美子, 打浪 雄介, 高橋 周平, 小泉 富基, 森 崇, 西岡 健太郎, 田口 大志, 橋本 孝之, 高邑 明夫, 西岡 井子, 北原 利博, 土屋 和彦, 井上 哲也, 有本 卓郎, 出倉 康裕, 米坂 祥朗, 鈴木 恵士郎, 川島 和之, 小野寺 俊輔, 喜多村 圭, 長谷川 雅一, 鬼丸 力也, 富田 雅義, 池田 潤, 西山 典明, 青山 英史
北海道放射線医学雑誌 = Hokkaido Journal of Radiology, 2, 13, 18, [札幌] : 北海道放射線医学雑誌, 2022年03月, ［査読有り］, ［国内誌］
日本語

症例 S-1併用陽子線治療後conversion surgeryを行った切除不能局所進行膵癌の1例:症例報告と文献レビュー
小泉 富基, 加藤 徳雄, 中村 透, 川本 泰之, 高尾 聖心, 阿保 大介, 清水 伸一, 青山 英史
臨床放射線, 66, 8, 827, 833, 金原出版, 2021年08月10日, ［査読有り］, ［筆頭著者］, ［国内誌］

SMARCB1欠損篩骨洞癌に対する強度変調陽子線治療 : 症例報告と文献レビュー—Intensity-Modulated Proton Therapy for SMARCB1-deficient Carcinoma of Ethmoid Sinus : A Case Report and Literature Review
宮﨑 智彦, 安田 耕一, 志藤 元泰, 小泉 富基, 藤田 祥博, 高橋 周平, 湊川 英樹, 大塚 愛美, 加藤 徳雄, 清水 伸一, 青山 英史
北海道放射線医学雑誌 = Hokkaido Journal of Radiology, 1, 1, 6, [札幌] : 北海道放射線医学雑誌, 2021年03月, ［査読有り］, ［国内誌］
日本語

Compartment model predicting dynamic radiation-induced lymphocyte depletion in NSCLC radiotherapy　　　　　　　　　　　　　　　
Takahiro Kanehira, Hiroshi Taguchi, Fuki Koizumi, Koichi Miyazaki, Taisuke Takayanagi, Norio Kato, Keiji Kobashi, Takayuki Hashimoto, Hidefumi Aoyama, The Federation of Asian Organization For Raditation Oncology 36th Annual Meeting, 2025年11月

Assessing Adaptive Proton Beam Therapy for Pancreatic Cancer Based on Daily CT-based Dose Evaluation　　　　　　　　　　　　　　　
Kaixin Du, Norio Katoh, Keiji Nakazato, Masaya Tamura, Fuki Koizumi, Yuto Matsuo, Takuya Matsumoto, Takahiro Kanehira, Izuru Otake, Yoshikazu Maeda, Makoto Sasaki, Yoshitaka Sato, Keiji Kobashi, Hiroyasu Tamamura, Hidefumi Aoyama, The Federation of Asian Organization For Raditation Oncology 36th Annual Meeting, 2025年11月

Short-term Outcomes of SIMT-VMAT SRT with Dose Reduction for Minute Brain Metastases　　　　　　　　　　　　　　　
Kentaro Nishioka、Ruja Vichitvejpaisal、Takashi Mori、Ryota Yamada、Shuhei Takahashi、Fuki Koizumi、Koichi Yasuda、Norio Katoh、Takayuki Hashimoto、Hidefumi Aoyama, The Federation of Asian Organization For Raditation Oncology 36th Annual Meeting, 2025年11月

Late Adverse Effects after High-Precision Radiotherapy for Malignant Sinonasal Tumours　　　　　　　　　　　　　　　
Koichi Yasuda, Shuhei Takahashi, Tomohiko Miyazaki, Fuki Koizumi, Takashi Mori, Kentaro Nishioka, Satoshi Kano, Norio Katoh, Akihiro Homma, Takayuki Hashimoto, Hidefumi Aoyama, The Federation of Asian Organization For Raditation Oncology 36th Annual Meeting, 2025年11月

肝細胞癌に対する動体追跡照射システムを用いた強度変調SBRTの後方視的検討　　　　　　　　　　　　　　　
岩佐 拓真, 加藤 徳雄, 高橋 周平, 小泉 富基, 宮本 直樹, 金平 孝博, 横川 航平, 鈴木 隆介, 阿保 大介, 青山 英史, 日本放射線腫瘍学会第38回学術大会, 2025年11月

外腸骨血管合併切除を要する大腸癌に対する安全な根治切除を目指した治療戦略　　　　　　　　　　　　　　　
今泉 健, 市川 伸樹, 吉田 雅, 大野 陽介, 柴田 賢吾, 佐野 峻司, 南田 大朗, 若狭 哲, 大西 貴士, 小泉 富基, 武冨 紹信, 第128回日本臨床外科学会北海道支部例会, 2025年09月

Daily CTを用いた線量評価による膵癌適応陽子線治療の有用性の検討　　　　　　　　　　　　　　　
杜開新, 加藤徳雄, 中里慧二, 田村昌也, 小泉富基, 前田嘉一, 佐藤義高, 玉村裕保, 小橋啓司, 青山英史, 第38回高精度放射線外部照射部会学術大会, 2025年05月

鼻副鼻腔悪性腫瘍に対する高精度放射線治療後の晩期障害　　　　　　　　　　　　　　　
安田耕一, 髙橋周平, 宮﨑智彦, 服部敬寛, 檜垣朔, 小泉富基, 対馬那由多, 加納里志, 本間明宏, 青山英史, 第38回高精度放射線外部照射部会学術大会, 2025年05月

多発性脳転移腫瘍に対するSingle-Isocenter Multi Target VMATを用いた定位放射線治療における治療中の患者の動きによる各標的の変位に関する検討　　　　　　　　　　　　　　　
山田亮太, 吉村高明, 村田凌, 西岡健太郎, 森崇, 小泉富基, 高橋周平, 山崎理衣, 橋本孝之, 青山英史, 第38回高精度放射線外部照射部会学術大会, 2025年05月

多発脳転移に対するSingle Isocenter Multi Target-VMATを用いた定位放射線治療の短期治療成績と、微小病変に対する線量低減の試み　　　　　　　　　　　　　　　
西岡健太郎, VichitvejpaisalRuja, 森崇, 山田亮太, 髙橋周平, 小泉富基, 安田耕一, 加藤徳雄, 橋本孝之, 青山英史, 第38回高精度放射線外部照射部会学術大会, 2025年05月

咽喉頭癌の高精度放射線治療における 治療途中の線量分布評価および 放射線治療計画変更に関する解析　　　　　　　　　　　　　　　
髙橋 周平, 安田 耕一, 服部 敬寛, 小泉 富基, 井戶川 寛志, 鈴木 崇祥, 対馬 那由多, 加納 里志, 本間 明宏, 山 英史, 第38回高精度放射線外部照射部会学術大会, 2025年05月

膵癌に対する傾向スコアマッチングを用いた陽子線治療とX線治療の放射線誘発リンパ球減少症および治療成績の比較　　　　　　　　　　　　　　　
小泉 富基, 加藤 徳雄, 川本 泰之, 中村 透, 柿坂 達彦, 阿保 大介, 金平 孝博, 高尾 聖心, 宮本 直樹, 青山 英史, 第38回高精度放射線外部照射部会学術大会, 2025年05月

Clinical Outcomes of Stereotactic Body Radiotherapy for Spinal Intramedullary Arteriovenous Malformations: A single Institutional Retrospective Review　　　　　　　　　　　　　　　
Ruja Vichitvejpaisal, Kentaro Nishioka, Toshiya Osanai, Motoyuki Iwasaki, Takashi Mori, Yusuke Uchinami, Tomohiko Miyazaki, Fuki Koizumi, Takayuki Hashimoto, Hidefumi Aoyama, The 84th Annual meeting of the Japan Radiological Society, 2025年04月

Initial report of postoperative radiotherapy including internal mammary lymph node region for breast cancer with volumetric modulated arc therapy (VMAT)　　　　　　　　　　　　　　　
Rumiko Kinoshita, Fuki Koizumi, Hajime Higaki, Takashi Mori, Kentaro Nishioka, Takayuki Hashimoto, Ryusuke Suzuki, Mistuchika Hosoda, Masato Takahashi, Hidefumi Aoyama, The 84th Annual meeting of the Japan Radiological Society, 2025年04月

Normal tissue complication probability model for severe radiation-induced lymphopenia in patients with pancreatic cancer treated with concurrent chemoradiotherapy　　　　　　　　　　　　　　　
Fuki Koizumi, Norio Katoh, Yasuyuki Kawamoto, Toru Nakamura, Tatsuhiko Kakisaka, Miyako Myojin, Noriaki Nishiyama, Akio Yonesaka, Isao Yokota, Hidefumi Aoyama, The 84th Annual meeting of the Japan Radiological Society, 2025年04月

Dosiomicsに基づく急性期放射線誘発口腔乾燥のリスク分類に関する検討　　　　　　　　　　　　　　　
高木天, 仲本宗泰, 安田耕一, 吉村高明, 田村弘詞, 藤井裕里, 小泉富基, 打浪雄介, 青山英史, 第127回日本医学物理学会学術大会, 2024年11月

膵癌化学放射線療法の放射線誘発リンパ球減少症に対する予測モデルの開発および検証　　　　　　　　　　　　　　　
小泉富基, 加藤徳雄, 金平孝博, 川本泰之, 中村透, 柿坂達彦, 明神美弥子, 西山典明, 米坂祥郎, 打浪雄介, 安田耕一, 西岡健太郎, 横田勲, 小橋啓司, 青山英史, 日本医学放射線腫瘍学会第37回学術大会, 2024年11月

視神経髄膜腫に対して 強度変調放射線治療を施行した1例　　　　　　　　　　　　　　　
髙橋周平, 西岡健太郎, 小泉富基, 檜垣朔, 打浪雄介, 森崇, 田村昌也, 青山 英史, 第150回日本医学放射線学会北日本地方会・第95回日本核医学会北日本地方会 2024年6月, 2024年06月

脊髄内動静脈奇形に対する体幹部定位放射線治療の遡及的検討　　　　　　　　　　　　　　　
西岡 健太郎, 森 崇, 打浪 雄介, 宮﨑 智彦, 小泉 富基, 橋本 孝之, 青山 英史, 第33回日本定位放射線治療学会, 2024年06月

膵癌に対するS-1併用陽子線治療の遡及的解析　　　　　　　　　　　　　　　
小泉富基, 加藤徳雄, 打浪雄介, 川本泰之, 中村透, 阿保大介, 金平孝博, 高尾聖心, 檜垣朔, 宮崎智彦, 高橋周平, 田口大志, 青山英史, 第150回日本医学放射線学会北日本地方会・第95回日本核医学会北日本地方会, 2024年06月

Prediction for gastrointestinal toxicity in patients with pancreatic cancer treated with concurrent chemoradiotherapy
Fuki Koizumi, Norio Katoh, Takahiro Kanehira, Yasuyuki Kawamoto, Toru Nakamura, Tatsuhiko Kakisaka, Yusuke Uchinami, Isao Yokota, Keiji Kobashi, Hidefumi Aoyama, The 83rd Annual meeting of the Japan Radiological Society, 2024年04月

85歳以上の超高齢者膵がんにおける定位放射線治療の経験　　　　　　　　　　　　　　　
立野涼仁、打浪雄介、加藤徳雄、宮崎智彦、安田耕一、小泉富基、高橋周平、金平孝博、宮本直樹、阿保大介、中村透、青山英史, 日本放射線腫瘍学会第36回学術大会, 2023年11月

上咽頭がんの治療成績と進行期症例に対する導入化学療法・補助化学療法に関する検討　　　　　　　　　　　　　　　
藤井裕里, 安田耕一, 打浪雄介, 江畑美織, 小泉富基, 檜垣朔, 宮崎智彦, 藤田祥博, 高橋周平, 大塚愛美, 田口純, 加納里志, 清水康, 本間明宏, 青山英史, 日本放射線腫瘍学会第36回学術大会, 2023年11月

Evaluation of the possibility of dose realignment adaptation by shifting the isocenter in proton beam therapy for pancreatic cancer　　　　　　　　　　　　　　　
N. Katoh, K. Nakazato, Y. Uchinami, T. Kanehira, S. Takahashi, F. Koizumi, H. Taguchi, K. Nishioka, K. Yasuda, M. Tamura, S. Takao, N. Miyamoto, T. Matsuura, K. Kobashi, H. Aoyama, ASTRO’s 63th Annual Meeting, 2023年10月

A risk prediction model for severe radiation induced lymphopenia in patients with pancreatic cancer treated with concurrent chemoradiotherapy　　　　　　　　　　　　　　　
Fuki Koizumi, Norio Katoh, Takahiro Kanehira, Yasuyuki Kawamoto, Toru Nakamura, Tatsuhiko Kakisaka, Yusuke Uchinami, Hiroshi Taguchi, Yoshihiro Fujita, Shuhei Takahashi, Hajime Higaki, Kentaro Nishioka, Koichi Yasuda, Rumiko Kinoshita, Ryusuke Suzuki, Naoki Miyamoto, Isao Yokota, Keiji Kobashi, Hidefumi Aoyama, ASTRO’s 65th Annual Meeting, 2023年10月

Predicting the daily gastrointestinal doses of stereotactic body radiation therapy for pancreatic cancer based on the shortest distance between the tumor and the gastrointestinal tract using daily computed tomography images　　　　　　　　　　　　　　　
Y. Uchinami, T. Kanehira, K. Nakazato, Y. Fujita, F. Koizumi, S. Takahashi, M. Otsuka, K. Yasuda, H. Taguchi, K. Nishioka, N. Miyamoto, K. Yokokawa, R. Suzuki, K. Kobashi, N. Katoh, H. Aoyama, ESTRO2023, 2023年05月

肝細胞癌陽子線治療効果予測におけるADC値指標の検討　　　　　　　　　　　　　　　
藤田 祥博, 加藤 徳雄, 打浪 雄介, 田口 大志, 西岡 健太郎, 森 崇, 安田 耕一, 小泉 富基, 大塚 愛美, 高尾 聖心, 田村 昌也, Sutherland Kenneth, Khin Khin Tha, 伊藤 陽一, 青山 英史, Japanese Journal of Radiology, 41, Suppl., 10, 10, 2023年02月
(公社)日本医学放射線学会, 日本語

膵癌に対する同時化学放射線療法の遡及的検討　　　　　　　　　　　　　　　
小泉富基, 加藤徳雄, 川本泰之, 中村透, 柿坂達彦, 田口大志, 打浪雄介, 西川昇, 志藤元泰, 藤田祥博, 木下留美子, 安田耕一, 西岡健太郎, 森崇, 橋本孝之, 青山英史, 日本医学放射線腫瘍学会第35回学術大会, 2022年11月

S-1併用陽子線治療後conversion surgeryを行った切除不能局所進行膵癌の1例　　　　　　　　　　　　　　　
小泉 富基, 加藤 徳雄, 打浪 雄介, 田口 大志, 青山 英史, 清水 伸一, 中村 透, 川本 泰之, 高尾 聖心, 田村 昌也, 松浦 妙子, 清水 伸一, Japanese Journal of Radiology, 40, Suppl., 3, 3, 2022年02月
(公社)日本医学放射線学会, 日本語

子宮頚癌に対する根治的放射線治療の治療成績
KINOSHITA Rumiko, UCHINAMI Yusuke, KOIZUMI Fuki, NISHIOKA Kentaro, HASHIMOTO Takayuki, KATO Fumi, MITAMURA Takashi, ITO Yoichi M, MATSUNO Yoshihiro, AOYAMA Hidefumi, 日本医学放射線学会総会抄録集, 81st, 2022年

A Dosimetric Analysis of Locoregional Failure Using Deformable Image Registration in Hypopharyngeal Cancer After Sequential-Boost Intensity-Modulated Radiotherapy　　　　　　　　　　　　　　　
M. Otsuka, K. Yasuda, H. Minatogawa, Y. Fujita, Y. Uchinami, F. Koizumi, R. Suzuki, N. Miyamoto, T. Suzuki, N. Tsushima, S. Kano, J. Taguchi, Y. Shimizu, A. Homma, S. Shimizu, H. Aoyama, ASTRO’s 63th Annual Meeting, 2021年11月

咽喉頭扁平上皮癌IMRTの照射中における線量分布変化に関する解析
安田 耕一, 打浪 雄介, 湊川 英樹, 小泉 富基, 大塚 愛美, 藤田 祥博, 井戸川 寛志, 鈴木 崇祥, 対馬 那由多, 加納 里志, 本間 明宏, 頭頸部癌, 47, 2, 210, 210, 2021年05月
(一社)日本頭頸部癌学会, 日本語

強度変調放射線療法(IMRT)による下咽頭癌の失敗と晩期毒性のパターン:遡及的分析
OTSUKA Manami, YASUDA Koichi, MINATOGAWA Hideki, DEKURA Yasuhiro, KOIZUMI Fuki, SUZUKI Ryusuke, SHIMIZU Yasushi, HOMMA Akihiro, SHIMIZU Shinichi, AOYAMA Hidefumi, 日本医学放射線学会総会抄録集, 80th, 2021年

嗅神経芽細胞腫に対する強度変調放射線療法の治療成績
MORI Takashi, MINATOGAWA Hideki, YASUDA Koichi, KOIZUMI Fuki, OTSUKA Manami, AOYAMA Hidefumi, 日本医学放射線学会総会抄録集, 80th, 2021年

動体追跡照射装置を用いた膵癌SBRTの初期経験　　　　　　　　　　　　　　　
小泉富基, 加藤徳雄, 金平孝博, 宮本直樹, 中村透, 阿保大介, 田口大志, 安田耕一, 西岡健太郎, 森崇, 打浪雄介, 西川昇, 大塚愛美, 藤田祥博, 青山英史, 日本医学放射線腫瘍学会第34回学術大会, 2021年

当院における膵癌に対する体幹部定位放射線治療（SBRT）の初期経験　　　　　　　　　　　　　　　
小泉富基, 加藤徳雄, 中村透, 阿保大介, 打浪雄介, 田口大志, 金平孝博, 宮本直樹, 清水伸一, 青山英史, 第30回日本定位放射線治療学会, 2021年

膵癌に対するS-1併用術前化学放射線療法(S-1併用NACRT)の治療成績
小泉 富基, 加藤 徳雄, 中村 透, 川本 泰之, 田口 大志, 打浪 雄介, 清水 伸一, 青山 英史, 日本医学放射線学会秋季臨床大会抄録集, 56回, S103, S103, 2020年10月
(公社)日本医学放射線学会, 日本語

全身の関節周囲の多発腫瘤が診断の契機となった慢性結節性痛風の1例　　　　　　　　　　　　　　　
小泉 富基, 坂本 圭太, 真鍋 徳子, 加藤 扶美, 工藤 與亮, 加藤 将, Japanese Journal of Radiology, 38, Suppl., 8, 8, 2020年02月
(公社)日本医学放射線学会, 日本語

切除可能境界（BR）膵癌に対するS-1併用術前化学放射線療法（S-1併用NACRT）の治療成績　　　　　　　　　　　　　　　
小泉富基, 加藤徳雄, 中村透, 川本泰之, 田口大志, 打浪雄介, 安田耕一, 清水伸一, 青山英史, 第122回北海道癌談話会, 第100回北海道医学大会腫瘍分科会, 2020年

偶発的に発見された尿道原発悪性リンパ腫の1例
中川 純一, 小川 肇, 小黒 武雄, 安井 太一, 小泉 富基, 堤 豊, 下山 則彦, 日本医学放射線学会秋季臨床大会抄録集, 55回, S480, S481, 2019年09月
(公社)日本医学放射線学会, 日本語

当科におけるViabahnの初期使用経験
小泉富基, 阿保大介, 曽山武士, 森田亮, 吉野裕紀, 木村輔, 工藤與亮, 日本インターベンショナルラジオロジー学会雑誌(Web), 34, 2, 2019年

FDG集積パターンからみるIgG4関連疾患とサルコイドーシスの比較　　　　　　　　　　　　　　　
小泉富基, 平田健司, 小林健太郎, 渡邊史郎, 古家翔, 工藤與亮, 志賀哲, Japanese Journal of Radiology, 2018年04月

【がん免疫療法の展望:免疫チェックポイント阻害薬の併用療法を中心に】免疫チェックポイント阻害薬の併用療法のエビデンス 免疫チェックポイント阻害薬と放射線治療　　　　　　　　　　　　　　　
安田 耕一, 志藤 元泰, 小泉 富基, 高橋 周平, 藤田 祥博, 大塚 愛美, 宮崎 智彦, 西川 昇, 打浪 雄介, 森 崇, 西岡 健太郎, 木下 留美子, 田口 大志, 加藤 徳雄, 橋本 孝之, 青山 英史
月刊 腫瘍内科, 2020年07月

DP-CAR術前の血流改変術　　　　　　　　　　　　　　　
阿保 大介, 中村 透, 曽山 武士, 森田 亮, 吉野 裕紀, 木村 輔, 金谷 本真, 小泉 富基, 工藤 與亮, 平野 聡
日本インターベンショナルラジオロジー学会雑誌, 39-3, 229-235, 2018年11月

放射線治療の副作用と緩和療法　　　　　　　　　　　　　　　
小泉富基
苫小牧市立病院 副作用対応を含めた放射線療法の推進に関する研修会, 2026年01月

押さえておきたい緩和的/緊急放射線治療　　　　　　　　　　　　　　　
小泉富基
北海道大学病院 腫瘍センターセミナー, 2024年10月

病気を治すだけじゃない〜QOLを維持するための放射線治療〜　　　　　　　　　　　　　　　
小泉富基
旭川厚生病院 Cancer Web Seminar, 2023年11月

比べてみよう放射線治療計画!~コツとポイント~　　　　　　　　　　　　　　　
小泉富基
Radiation Oncology skill up seminar in Hokkaido, 2021年03月